Novartis (NVS) on Thursday announced that the European Commission approved its gene therapy. Itvisma (onasemnogene abeparvovec) for children aged two years and older with spinal muscular atrophy, a ...

Novartis already received FDA approval of ITVISMA as a gene therapy for the treatment of patients with SMA. Read why NVS ...

Adam Friedman, CEO of the Scorpion Therapeutics spinout, said the deal helps both companies accelerate research "faster than ...

Find out what Novartis' pipeline strategy since it spun off its biosimilars and generics business Sandoz, and engage in ...

The approval is supported by data from the STEER, Phase IIIb STRENGTH and Phase I/II STRONG studies.

Novartis stock has almost doubled investors' money over the past five years, yet current valuation checks still lean toward the shares looking inexpensive relative to underlying fundamentals. This ...

European Commission approves Novartis' Itvisma gene replacement therapy for spinal muscular atrophy across children, teens, ...

As a sweltering heat wave hit Europe, a swath of pharma companies and healthcare marketing agencies from around the world ...

Basel, July 2, 2026 – Novartis today announced that the European Commission (EC) has approved Itvisma ® (onasemnogene ...

Antares’ lead precision oncology programme is expected to enter the clinic in 2026.

Novartis (NVS) stock is in focus as the company collaborates with Antares Therapeutics to develop cancer drugs in a deal ...

The prostate cancer screening campaign launched during Super Bowl LX led the 2026 Pharma Lions, while work from Viatris, ...